Argenx Se (ARGX) Prepaid Assets (2015 - 2026)
Argenx Se's (ARGX) quarterly Prepaid Assets came in at $572.0 million in Q2 2026, down 99.84% YoY from $362.7 billion in Q2 2025, and up 74.39% on a QoQ basis from $328.0 million in Q4 2025.
Argenx Se (ARGX) Prepaid Assets (2015 - 2026) Analysis & Trends
Argenx Se (ARGX) has 12 years of Prepaid Assets data on file, last reported at $572.0 million in Q2 2026.
- Quarterly Prepaid Assets fell 99.84% year-over-year to $572.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $572.0 million (down 99.84% YoY) and the FY2025 annual result came in at $328.0 million, up 74.52% from the prior year.
- Prepaid Assets rose to $572.0 million in Q2 2026, from $328.0 million in the prior quarter.
- In the past five years, Prepaid Assets ranged from a high of $362.7 billion in Q2 2025 to a low of $76.0 million in Q4 2022.
- A 5-year average of $40.5 billion and a median of $179.4 million in 2024 frame the typical range for Prepaid Assets.
- Annual changes were most pronounced in 2025 — Prepaid Assets soared 202059.74% — and 2026, when it tumbled 99.84%.
- Tracing ARGX's Prepaid Assets over 5 years: stood at $76.0 million in 2022, then jumped by 76.36% to $134.1 million in 2023, then jumped by 40.18% to $187.9 million in 2024, then jumped by 74.52% to $328.0 million in 2025, then soared by 74.39% to $572.0 million in 2026.
- The last three Prepaid Assets figures came in at $572.0 million (Q2 2026), $328.0 million (Q4 2025), and $362.7 billion (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 572.00 Mn |
| Dec 31, 2025 | 328.00 Mn |
| Jun 30, 2025 | 362.72 Bn |
| Dec 31, 2024 | 187.95 Mn |
| Jun 30, 2024 | 179.42 Mn |
| Dec 31, 2023 | 134.07 Mn |
| Jun 30, 2023 | 138.83 Mn |
| Dec 31, 2022 | 76.02 Mn |
| Jun 30, 2022 | 82.31 Mn |
| Dec 31, 2021 | 58.95 Mn |
| Jun 30, 2021 | 62.40 Mn |
| Dec 31, 2020 | 27.12 Mn |
| Jun 30, 2020 | 11.97 Mn |
| Dec 31, 2019 | 9.99 Mn |
| Jun 30, 2019 | 9.36 Mn |
| Dec 31, 2018 | 3.42 Mn |
| Jun 30, 2018 | 5.63 Mn |
| Dec 31, 2017 | 2.75 Mn |
| Jun 30, 2017 | 2.59 Mn |
| Dec 31, 2016 | 2.32 Mn |